Drugs / YS-HBV-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06162299 | Jul → Sep 2024 | chronic hepatitis B virus infection | Yisheng Biopharma (Singapore) Pte. Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YS-HBV-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06162299 ↗ |
| Modality | Vaccine | “YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant” NCT06162299 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT06162299 ↗ |